Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Will Address Rebates And “Retail Class Of Trade” In AMP Regulation

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency commented on an HHS Office of Inspector General report that found inconsistencies in average manufacturer price calculations.

You may also be interested in...

CMS Will Delay Publication Of Average Manufacturer Prices

The agency agrees with pharmacy groups that the pricing benchmarks would not be accurate; regulation development will be CMS’ initial focus.

NACDS Seeks Delay In Manufacturer Price Reporting Requirements

Pharmacy trade group says average manufacturer prices should not be made public due to calculation inconsistencies.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts